MELVILLE, N.Y., March 7, 2017 /PRNewswire/ -- Cystic fibrosis is
a genetic disease that causes persistent lung infections and, over
time, limits the ability to breathe. A defective gene, the cystic
fibrosis transmembrane conductance regulator (CFTR) gene, causes
secretions that are normally slippery and thin to become sticky and
viscous. The secretions build up in the lungs, pancreas, and other
organs. In the lungs, the secretions clog the airways and trap
bacteria, which leads to infections, extensive lung damage, and
eventual respiratory failure. In the pancreas, the secretions
prevent the release of digestive enzymes that allow the body to
break down food and absorb vital nutrients. As an inherited
disorder, mutations in the CFTR gene cause the disease; however,
the severity of the disease depends on the actual gene
mutation.
Canon BioMedical understands that researchers are performing
important CFTR research, and we developed 21 Novallele genotyping
assays to detect single-nucleotide polymorphisms (SNPs) and
deletions within the CFTR gene. The Novallele genotyping
assays detect genetic variations using polymerase chain reaction
(PCR) followed by high-resolution melting (HRM) analysis on any
thermocycler capable of HRM. All Novallele genotyping assays are
functionally verified and focus on genotypes relevant to genetic
researchers working to improve health and advance science.
"We are excited to launch these new CFTR assays and add
them to our Novallele genotyping assay library," states
Akiko Tanaka, CEO of Canon
BioMedical. "Cystic fibrosis directly affects the quality of life
of thousands of people, and we can only hope that our technologies
will contribute to understanding this complex disease and assist
with the ongoing therapeutic research."
Complete details about the entire Novallele genotyping assays
are available at www.canon-biomedical.com. In addition, Canon
BioMedical will present the Novallele genotyping library at the
American College of Medical Genetics and Genomics 2017 Annual
Meeting in Phoenix, Arizona, on
March 21, 2017. Find us at Booth 412
in the exhibit hall to discover more about our new assays focused
on cystic fibrosis research.
About Canon BioMedical
Canon BioMedical, a wholly owned subsidiary of Canon
U.S.A., Inc., is focused on
empowering the biomedical research and healthcare communities by
developing, manufacturing, and marketing innovative technologies
and solutions. The technologies and solutions developed will help
enable clinicians and scientists to improve our health and advance
science. Canon BioMedical will continue to pursue innovative
solutions in line with Canon's Kyosei philosophy of social
and environmental responsibility through the use of existing and
emerging Canon technology as well as strategic partnerships.
Products mentioned in this release are for Research Use Only.
Not for use in diagnostic procedures.
All referenced product names, and other marks, are trademarks of
their respective owners.
© 2017 Canon BioMedical, Inc. All rights reserved.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cystic-fibrosis-research-assays-are-the-latest-additions-to-canon-biomedicals-novallele-genotyping-library-300419366.html
SOURCE Canon U.S.A., Inc.